TARRYTOWN, N.Y., Aug. 2, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it will host a conference call and webcast to discuss its financial results for the second quarter of 2011 on Tuesday, August 9, 2011 at 8:30 a.m. ET.
To join the conference call, please dial 877-250-8889 (domestic) or 720-545-0001 (international). The access code for the live call is 88334481. A telephone replay of the call will be available for one week following. To listen to the replay, please dial 800-871-9012 and extension 885867# (domestic) or 641-715-3900 and 925289# (international). The live webcast will be available on the Events page of the Company's website and archived for 30 days.
Progenics Pharmaceuticals, Inc., of Tarrytown, NY, USA, is a biopharmaceutical company with programs in gastroenterology, oncology and virology focused on innovative therapeutics for patients with debilitating conditions and life-threatening diseases. Progenics' first commercialized therapy is RELISTOR(R) (methylnaltrexone bromide), a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness. Progenics has exclusively licensed Salix Pharmaceuticals, Ltd. to continue development and commercialization of RELISTOR in worldwide markets other than Japan, where Ono Pharmaceutical Co., Ltd. has an exclusive license to develop and commercialize subcutaneous RELISTOR. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 1 testing for treatment of prostate cancer, and preclinical stage, novel antibodies to toxins produced by C. difficile bacteria.
(PGNX-G)